Pratteln, Switzerland, March 10, 2021 -- Santhera Pharmaceuticals (SIX: 
SANN) announces that it has issued 480,708 treasury shares. The number 
of shares recorded in the commercial register has been increased to 
21,510,404 shares. 
 
   On March 9, 2021, and as announced when calling the extraordinary 
general meeting of shareholders scheduled for March 18, 2021, 480,708 
shares were issued out of the existing authorized capital as treasury 
shares. Santhera expects to use these shares for purposes of its 
financing arrangements. The new shares will be listed as per March 10, 
2021. 
 
   About Santhera 
 
   Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical 
company focused on the development and commercialization of innovative 
medicines for rare neuromuscular and pulmonary diseases with high unmet 
medical need. Santhera has an exclusive license for all indications 
worldwide to vamorolone, a first-in-class dissociative steroid with 
novel mode of action, currently investigated in a pivotal study in 
patients with DMD as an alternative to standard corticosteroids. The 
clinical stage pipeline also includes lonodelestat (POL6014) to treat 
cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well 
as an exploratory gene therapy approach targeting congenital muscular 
dystrophies. Santhera out-licensed ex-North American rights to its first 
approved product, Raxone(R) (idebenone), for the treatment of Leber's 
hereditary optic neuropathy (LHON) to Chiesi Group. For further 
information, please visit 
https://www.globenewswire.com/Tracker?data=n0cgsh_d2b8tS1KfTixAzN4q_O-DrXt_hWj7_Wu3QyvoIkaosmqb1TiC8X0cVXt9FPGGdeXdziRUu53vpQj0Ig== 
www.santhera.com. 
 
   Raxone(R) is a trademark of Santhera Pharmaceuticals. 
 
   For further information please contact: 
 
   https://www.globenewswire.com/Tracker?data=khWPF7nvlVHrVBQqI_HyjPQeWi28fgG2uFposzae9jyj1qaePNg-9E35gOtssT9AUbBd1p1QwRlsgaCcQ0WJhk9hqXQ20VbWpWjKv9HFz8HWPkWR17HAJqzfbqi_ePzH 
public-relations@santhera.com or 
 
   Eva Kalias, Head External Communications 
 
   Phone: +41 79 875 27 80 
 
   eva.kalias@santhera.com 
 
   Disclaimer / Forward-looking statements 
 
   This communication does not constitute an offer or invitation to 
subscribe for or purchase any securities of Santhera Pharmaceuticals 
Holding AG. This publication may contain certain forward-looking 
statements concerning the Company and its business. Such statements 
involve certain risks, uncertainties and other factors which could cause 
the actual results, financial condition, performance or achievements of 
the Company to be materially different from those expressed or implied 
by such statements. Readers should therefore not place undue reliance on 
these statements, particularly not in connection with any contract or 
investment decision. The Company disclaims any obligation to update 
these forward-looking statements. 
 
   # # # 
 
   Attachment 
 
 
   -- 2021 03 10_CapIncreaseFinancings_e_finalx 
      https://ml-eu.globenewswire.com/Resource/Download/74ef47d3-7a12-4c18-b858-12f3d72cc6f0

(END) Dow Jones Newswires

March 10, 2021 01:00 ET (06:00 GMT)